Hydrocortisone-Cortisol-DataSheet-生命科學(xué)試劑-MedChemExpress

Hotline:400-820-3792Inhibitors?ScreeningLibraries?Proteinswww.MedChemEHydrocortisoneCat.No.:HY-N0583CASNo.:50-23-7Synonyms:Cortisol分?式:C??H??O?分?量:362.46作?靶點:GlucocorticoidReceptor;EndogenousMetabolite作?通路:Immunology/Inflammation;MetabolicEnzyme/Protease儲存?式:4°C,protectfromlight*Insolvent:-80°C,6months;-20°C,1month(protectfrom

light)溶解性數(shù)據(jù)體外實驗DMSO:≥31mg/mL(85.53mM)H2O:<0.1mg/mL(insoluble)*"≥"meanssoluble,butsaturationunknown.MassSolvent1mg5mg10mgConcentration制備儲備液1mM2.7589mL13.7946mL27.5893mL5mM0.5518mL2.7589mL5.5179mL10mM0.2759mL1.3795mL2.7589mL請根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液；?旦配成溶液，請分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。儲備液的保存?式和期限：-80°C,6months;-20°C,1month(protectfromlight)。-80°C儲存時，請在6個?內(nèi)使?，-20°C儲存時，請在1個?內(nèi)使?。體內(nèi)實驗請根據(jù)您的實驗動物和給藥?式選擇適當(dāng)?shù)娜芙?案。以下溶解?案都請先按照InVitro?式配制澄的儲備液，再依次添加助溶劑：(為保證實驗結(jié)果的可靠性，澄的儲備液可以根據(jù)儲存條件，適當(dāng)保存；體內(nèi)實驗的?作液，建議您現(xiàn)?現(xiàn)配，當(dāng)天使?；以下溶劑前顯?的百分?指該溶劑在您配制終溶液中的體積占?；如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的?式助溶)1/3MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemE1.請依序添加每種溶劑：10%DMSO>>40%PEG300>>5%Tween-80>>45%salineSolubility:≥2.5mg/mL(6.90mM);Clearsolution2.請依序添加每種溶劑：10%DMSO>>90%(20%SBE-β-CDinsaline)Solubility:≥2.08mg/mL(5.74mM);Clearsolution3.請依序添加每種溶劑：10%DMSO>>90%cornoilSolubility:≥2.08mg/mL(5.74mM);Clearsolution4.請依序添加每種溶劑：5%DMSO>>40%PEG300>>5%Tween-80>>50%salineSolubility:≥2.5mg/mL(6.90mM);Clearsolution5.請依序添加每種溶劑：5%DMSO>>95%(20%SBE-β-CDinsaline)Solubility:≥2.5mg/mL(6.90mM);ClearsolutionBIOLOGICALACTIVITY?物活性Hydrocortisone(Cortisol)腎上腺?質(zhì)分泌的類醇激素或糖?質(zhì)激素[1]。IC50&TargetHumanEndogenousMetaboliteHumanEndogenousMetabolite體外研究Hydrocortisone(50nM)showsadose-dependentdown-regulationofGRtranscriptinhCMEC/D3cells.Hydrocortisonesupplementationoftheserum-reducedcelldifferentiationmediumleadstoasignificantincreaseinTERacrossthehCMEC/D3monolayer[1].Hydrocortisone-treatedDendriticcells(DCs)showadecreasedexpressionofMHCIImolecules,thecostimulatorymoleculeCD86,andtheDC-specificmarkerCD83,aswellasastronglyreducedIL-12secretion.Hydrocortisone-treatedDCsinhibitproductionofIFN-γbutinduceanincreasedreleaseofIL-4andnochangeinIL-5[2].Hydrocortisonereducespostischemicoxidativestress,perfusionpressure,andtransudateformation.Hydrocortisoneinhibitspostischemicsheddingofsyndecan-1,heparansulfate,andhyaluronanasisreleaseofhistaminefromresidentmastcells[3].PROTOCOLCellAssay[1]CellsareplatedontopofcollagenIV-coatedtranswellchambersforsix-wellplates(24mmdiameter,membranematerial:polyethyleneterephthalate(PET),0.4μmpores,poredensity1.6×106cm2)atdensitiesof2.5×104cellscm2perwell.Whentheyhavereachedconfluenceatday5,thedifferentexperimentalsetsofcellsaretransferredtodifferentiationmediumcontainingreducedamountsofFCSandtreatedwithTNFαorhydrocortisoneasindicated.MCEhasnotindependentlyconfirmedtheaccuracyofthesemethods.Theyareforreferenceonly.戶使?本產(chǎn)品發(fā)表的科研?獻?Nature.2021Jan;589(7843):620-626.?NatChemBiol.2022Aug18.?CancerCommun(Lond).2021Jul;41(7):576-595.?JCIInsight.2021Jun22;6(12):142838.2/3MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemE?OxidMedCellLongev.2022Jan27;2022:7502632.Seemorecustomervalidationsonwww.MedChemEREFERENCES[1].F?rsterC,etal.DifferentialeffectsofhydrocortisoneandTNFalphaontightjunctionproteinsinaninvitromodelofthehumanblood-brainbarrier.JPhysiol.2008Apr1;586(7):1937-49.[2].BellinghausenI,etal.InhibitionofhumanallergicT-cellresponsesbyIL-10-treateddendriticcells:differencesfromhydrocortisone-treateddendriticcells.JAllergyClinImmunol.2001Aug;108(2):242-9.[3].ChappellD,etal.Hydrocortisonepreservesthevascularbarrierbyprotectingtheendothelialglycocalyx.Anesthesiology.2007Nov;107(5):776-84.McePdfHeigh